{"id":"fluoxetine-olanzapine","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Metabolic syndrome risk"}]},"_chembl":null,"_dailymed":{"setId":"3c28cf18-01a3-468a-ab3e-8aa82f918251","title":"OLANZAPINE AND FLUOXETINE CAPSULE [TEVA PHARMACEUTICALS USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors. This combination leverages both monoamine systems to treat mood and psychotic symptoms simultaneously.","oneSentence":"Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:44.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Bipolar I disorder depression"}]},"trialDetails":[{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT04876521","phase":"PHASE4","title":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-10-14","conditions":"Post-Schizophrenic Depression","enrollment":60},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT01687478","phase":"PHASE3","title":"A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2012-09","conditions":"Treatment Resistant Depression","enrollment":176},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT00339079","phase":"PHASE1, PHASE2","title":"Treatment of Hypochondriasis With CBT and/or SSRI","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-06","conditions":"Hypochondriasis","enrollment":195},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT02593734","phase":"PHASE4","title":"Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana","status":"COMPLETED","sponsor":"University of Ghana Medical School","startDate":"2013-07","conditions":"Schizophrenia, Mood Disorders,, Anxiety Disorder","enrollment":139},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00489593","phase":"PHASE1","title":"Olanzapine in Patients With Advanced Cancer and Weight Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-10","conditions":"Advanced Cancer, Weight Loss","enrollment":57},{"nctId":"NCT00958568","phase":"PHASE3","title":"A Study in Relapse Prevention of Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Treatment Resistant Depression","enrollment":892},{"nctId":"NCT00000373","phase":"PHASE4","title":"Treatment of Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"University of Florida","startDate":"1992-09","conditions":"Obsessive-Compulsive Disorder","enrollment":74},{"nctId":"NCT00844857","phase":"PHASE4","title":"A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":291},{"nctId":"NCT00188942","phase":"PHASE4","title":"A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2005-02","conditions":"Major Depressive Disorder","enrollment":42},{"nctId":"NCT00512291","phase":"NA","title":"Subcutaneous Olanzapine for Hyperactive or Mixed Delirium","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-06","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27},{"nctId":"NCT01000402","phase":"PHASE4","title":"Juvenile Bipolar Disorder Outpatient Program","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2008-02","conditions":"Bipolar Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":150},{"nctId":"NCT00485810","phase":"PHASE1, PHASE2","title":"Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-06","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT00485901","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-07","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00485498","phase":"PHASE4","title":"Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-04","conditions":"Schizophrenia","enrollment":122},{"nctId":"NCT00486005","phase":"PHASE4","title":"Weight Gain Management in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-02","conditions":"Schizophrenia","enrollment":74},{"nctId":"NCT00485680","phase":"PHASE3","title":"Olanzapine Versus Comparator in the Treatment of Bipolar Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-12","conditions":"Bipolar Disorder","enrollment":140},{"nctId":"NCT00485771","phase":"PHASE4","title":"Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-11","conditions":"Bipolar Disorder","enrollment":403},{"nctId":"NCT00485823","phase":"PHASE4","title":"Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-12","conditions":"Schizophrenic Disorders","enrollment":48},{"nctId":"NCT00191399","phase":"PHASE4","title":"Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-05","conditions":"Depression, Bipolar","enrollment":150},{"nctId":"NCT00035321","phase":"PHASE3","title":"The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-04","conditions":"Major Depressive Disorder","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluoxetine+Olanzapine","genericName":"Fluoxetine+Olanzapine","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects. Used for Treatment-resistant depression, Bipolar I disorder depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}